熱門資訊> 正文

Gossamer Bio提交Seralutinib治疗肺动脉高压的NDA

2026-09-24 06:16

Gossamer Bio(GOSS) 0
碩迪生物(GPCR) 0

Gossamer Bio (GOSS) has submitted an NDA to the US FDA seeking approval of seralutinib for pulmonary arterial hypertension (PAH).
The application is supported by data from the phase 3 PROSERA study, evidence from the phase 2 TORREY study, and supportive analyses.
Results from the phase 3 trial, released in February, found that seralutinib did not meet its primary endpoint, placebo-adjusted improvement in Six-Minute Walk Distance (6MWD), as the results missed statistical significance.
The NDA submission is the first for Gossamer.

More on Gossamer Bio

Gossamer Bio, Inc. (GOSS) Discusses Reacquisition of Seralutinib Rights, Regulatory Progress and Capital Structure Updates Transcript
Gossamer Bio announces up to $250M private placement
Seeking Alpha’s Quant Rating on Gossamer Bio
Historical earnings data for Gossamer Bio
Financial information for Gossamer Bio

推薦文章

風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。